Is NRXS or CV more profitable?

CapsoVision has a net margin of -214.74% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% CapsoVision -214.74% -177.85% -135.07%

Is NRXS or RCEL more profitable?

Avita Medical has a net margin of -56.96% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Avita Medical -56.96% N/A -78.53%

Does the media prefer NRXS or RCEL?

In the previous week, Avita Medical had 5 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for Avita Medical and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.91 beat Avita Medical's score of 0.56 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRXS or TMCI?

In the previous week, Treace Medical Concepts had 8 more articles in the media than NeurAxis. MarketBeat recorded 9 mentions for Treace Medical Concepts and 1 mentions for NeurAxis. Treace Medical Concepts' average media sentiment score of 1.43 beat NeurAxis' score of 0.91 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Treace Medical Concepts 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNXU or NRXS more profitable?

Conexeu Sciences has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets Conexeu Sciences N/A N/A N/A NeurAxis -492.76% N/A -641.25%

Is PROF or NRXS more profitable?

Profound Medical has a net margin of -171.57% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets Profound Medical -171.57% -63.03% -51.24% NeurAxis -492.76% N/A -641.25%

NeurAxis (NRXS) Competitors

$6.04 -0.03 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$6.02 -0.02 (-0.31%)

As of 05:33 PM Eastern

Compare

NRXS vs. CV, RCEL, TMCI, CNXU, and PROF

Should you buy NeurAxis stock or one of its competitors? NeurAxis's main competitors and comparable companies include CapsoVision (CV), Avita Medical (RCEL), Treace Medical Concepts (TMCI), Conexeu Sciences (CNXU), and Profound Medical (PROF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeurAxis compare to CapsoVision?

NeurAxis (NASDAQ:NRXS) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

NeurAxis has higher earnings, but lower revenue than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	14.27	-$14.63M	-$0.78	N/A
CapsoVision	$13.55M	21.61	-$25.32M	-$0.47	N/A

NeurAxis currently has a consensus target price of $13.00, suggesting a potential upside of 115.23%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 45.30%. Given NeurAxis' stronger consensus rating and higher probable upside, equities analysts plainly believe NeurAxis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CapsoVision has a net margin of -214.74% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
CapsoVision	-214.74%	-177.85%	-135.07%

11.8% of NeurAxis shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NeurAxis and NeurAxis both had 1 articles in the media. NeurAxis' average media sentiment score of 0.91 beat CapsoVision's score of 0.00 indicating that NeurAxis is being referred to more favorably in the media.

Company	Overall Sentiment
NeurAxis	Positive
CapsoVision	Neutral

Summary

NeurAxis beats CapsoVision on 8 of the 14 factors compared between the two stocks.

How does NeurAxis compare to Avita Medical?

NeurAxis (NASDAQ:NRXS) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

NeurAxis has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Avita Medical has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market.

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Avita Medical has a net margin of -56.96% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Avita Medical	-56.96%	N/A	-78.53%

NeurAxis currently has a consensus target price of $13.00, suggesting a potential upside of 115.23%. Avita Medical has a consensus target price of $10.20, suggesting a potential downside of 2.86%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

NeurAxis has higher earnings, but lower revenue than Avita Medical. NeurAxis is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	14.27	-$14.63M	-$0.78	N/A
Avita Medical	$71.61M	4.51	-$48.59M	-$1.44	N/A

In the previous week, Avita Medical had 5 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for Avita Medical and 1 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.91 beat Avita Medical's score of 0.56 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avita Medical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeurAxis beats Avita Medical on 8 of the 15 factors compared between the two stocks.

How does NeurAxis compare to Treace Medical Concepts?

NeurAxis (NASDAQ:NRXS) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

NeurAxis has higher earnings, but lower revenue than Treace Medical Concepts. NeurAxis is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$5.32M	14.27	-$14.63M	-$0.78	N/A
Treace Medical Concepts	$212.69M	1.47	-$59M	-$0.93	N/A

Treace Medical Concepts has a net margin of -28.99% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

NeurAxis has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

In the previous week, Treace Medical Concepts had 8 more articles in the media than NeurAxis. MarketBeat recorded 9 mentions for Treace Medical Concepts and 1 mentions for NeurAxis. Treace Medical Concepts' average media sentiment score of 1.43 beat NeurAxis' score of 0.91 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Treace Medical Concepts	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeurAxis currently has a consensus price target of $13.00, suggesting a potential upside of 115.23%. Treace Medical Concepts has a consensus price target of $5.17, suggesting a potential upside of 7.48%. Given NeurAxis' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeurAxis is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

NeurAxis beats Treace Medical Concepts on 8 of the 15 factors compared between the two stocks.

How does NeurAxis compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Conexeu Sciences and Conexeu Sciences both had 1 articles in the media. NeurAxis' average media sentiment score of 0.91 beat Conexeu Sciences' score of 0.82 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Overall Sentiment
Conexeu Sciences	Positive
NeurAxis	Positive

11.8% of NeurAxis shares are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Conexeu Sciences presently has a consensus price target of $20.00, suggesting a potential upside of 164.90%. NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 115.23%. Given Conexeu Sciences' higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Conexeu Sciences has higher earnings, but lower revenue than NeurAxis. Conexeu Sciences is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A
NeurAxis	$5.32M	14.27	-$14.63M	-$0.78	N/A

Conexeu Sciences has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats Conexeu Sciences on 6 of the 11 factors compared between the two stocks.

How does NeurAxis compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Profound Medical presently has a consensus price target of $11.50, indicating a potential upside of 68.87%. NeurAxis has a consensus price target of $13.00, indicating a potential upside of 115.23%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Profound Medical has a net margin of -171.57% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
NeurAxis	-492.76%	N/A	-641.25%

In the previous week, Profound Medical and Profound Medical both had 1 articles in the media. NeurAxis' average media sentiment score of 0.91 beat Profound Medical's score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Overall Sentiment
Profound Medical	Neutral
NeurAxis	Positive

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeurAxis has lower revenue, but higher earnings than Profound Medical. NeurAxis is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.37	-$42.57M	-$0.98	N/A
NeurAxis	$5.32M	14.27	-$14.63M	-$0.78	N/A

Profound Medical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Summary

NeurAxis beats Profound Medical on 9 of the 15 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$75.85M	$5.96B	$7.34B	$12.72B
Dividend Yield	N/A	1.74%	2.53%	11.02%
P/E Ratio	-3.28	26.05	270.94	24.14
Price / Sales	14.27	70.20	634.77	96.69
Price / Cash	N/A	33.27	78.57	53.12
Price / Book	-22.37	6.27	13.14	6.25
Net Income	-$14.63M	$149.30M	$3.46B	$347.86M
7 Day Performance	-3.51%	0.98%	3.23%	1.57%
1 Month Performance	-11.18%	9.22%	8.82%	5.24%
1 Year Performance	137.80%	7.82%	27.70%	17.87%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	1.931 of 5 stars	$6.04 -0.5%	$13.00 +115.2%	+145.7%	$75.85M	$5.32M	N/A	19
CV CapsoVision	2.3247 of 5 stars	$6.12 -0.5%	$8.50 +38.9%	+45.8%	$307.79M	$13.55M	N/A	90
RCEL Avita Medical	2.0131 of 5 stars	$10.34 +5.0%	$10.20 -1.4%	+103.1%	$303.15M	$71.61M	N/A	130
TMCI Treace Medical Concepts	3.2935 of 5 stars	$4.56 +2.5%	$5.17 +13.4%	-43.2%	$289.40M	$212.69M	N/A	250	News Coverage Positive News Insider Trade Gap Up
CNXU Conexeu Sciences	3.8011 of 5 stars	$8.96 -10.3%	$20.00 +123.2%	N/A	$267.31M	N/A	N/A	4	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. CV, RCEL, TMCI, CNXU, and PROF

How does NeurAxis compare to CapsoVision?

Summary

How does NeurAxis compare to Avita Medical?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Summary

How does NeurAxis compare to Conexeu Sciences?

Summary

How does NeurAxis compare to Profound Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. CV, RCEL, TMCI, CNXU, and PROF

How does NeurAxis compare to CapsoVision?

Which has preferable valuation & earnings, NRXS or CV?

Do analysts recommend NRXS or CV?

Is NRXS or CV more profitable?

Do insiders and institutionals believe in NRXS or CV?

Does the media prefer NRXS or CV?

Summary

How does NeurAxis compare to Avita Medical?

Which has more risk & volatility, NRXS or RCEL?

Do institutionals and insiders believe in NRXS or RCEL?

Is NRXS or RCEL more profitable?

Do analysts rate NRXS or RCEL?

Which has stronger valuation & earnings, NRXS or RCEL?

Does the media prefer NRXS or RCEL?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Which has stronger earnings & valuation, NRXS or TMCI?

Is NRXS or TMCI more profitable?

Which has more risk & volatility, NRXS or TMCI?

Does the media refer more to NRXS or TMCI?

Do analysts recommend NRXS or TMCI?

Do institutionals & insiders hold more shares of NRXS or TMCI?

Summary

How does NeurAxis compare to Conexeu Sciences?

Does the media prefer CNXU or NRXS?

Do insiders and institutionals believe in CNXU or NRXS?

Do analysts rate CNXU or NRXS?

Which has preferable earnings & valuation, CNXU or NRXS?

Is CNXU or NRXS more profitable?

Summary

How does NeurAxis compare to Profound Medical?

Do analysts prefer PROF or NRXS?

Is PROF or NRXS more profitable?

Does the media prefer PROF or NRXS?

Do insiders & institutionals have more ownership in PROF or NRXS?

Which has stronger earnings and valuation, PROF or NRXS?

Which has more volatility & risk, PROF or NRXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools